Background <p>Cancer immunotherapy (CIT) often triggers immune-related adverse events (irAEs). Analysis of irAEs in large checkpoint inhibitor (CPI) trials has enhanced their management and demonstrated their prognostic value for treatment outcome. However, data on irAEs in non-standard CITs are limited, and systematic exploration is lacking. Identifying predictive biomarkers for irAEs in these therapies is still emerging and essential for improving…
Identification of conserved immune-related adverse event risk factors and clinical outcomes in a pan-immunotherapy data mart
Journal for ImmunoTherapy of Cancer | | Lamparter, D. F., Schmid, V. C., Mohindra, R., Karanikas, V., Kam-Thong, T., Scepanovic, P., Duchateau-Nguyen, G., Roller, A., Heinzmann, D., Adams, C., Mycroft, S. L., Fairfax, B. P., Staedler, N.
Topics: immunotherapy, targeted-therapy, prevention, research
Read the full article at Journal for ImmunoTherapy of Cancer